NCT00830518View on ClinicalTrials.gov

A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 10, 2009

Primary Completion Date

February 2, 2010

Study Completion Date

July 4, 2011

Conditions
Acute Myelogenous LeukemiaHigh-Grade Myelodysplastic Syndrome
Interventions
DRUG

Alisertib

Alisertib capsules

Trial Locations (1)

07962

Hematology and Oncology Associates of Northern New Jersey, Morristown

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY